Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs)

Piotr Rutkowski; Zbigniew I. Nowecki; Maria D?biec-Rychter; Urszula Grzesiakowska; Wanda Michej; Agnieszka Wo?niak; Janusz A. Siedlecki; Janusz Limon; Anna Jerzak vel Dobosz; Micha? K?kol; Czes?aw Osuch; W?odzimierz Ruka

首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs)

【24h】

Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs)

机译：伊马替尼治疗无法手术/转移性CD117（+）胃肠道间质瘤（GIST）患者的长期疗效的预测因素

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

To analyze the outcomes of treatment and factors predicting effects of imatinib (IM) therapy in inoperable/metastatic gastrointestinal stromal tumors (GIST) CD117(+) patients.

机译：分析治疗结果和预测伊马替尼（IM）治疗无法手术/转移性胃肠道间质瘤（GIST）CD117（+）患者的效果的因素。

著录项

来源
《Journal of Cancer Research and Clinical Oncology 》 |2007年第9期| 589-597| 共9页
作者
Piotr Rutkowski; Zbigniew I. Nowecki; Maria D?biec-Rychter; Urszula Grzesiakowska; Wanda Michej; Agnieszka Wo?niak; Janusz A. Siedlecki; Janusz Limon; Anna Jerzak vel Dobosz; Micha? K?kol; Czes?aw Osuch; W?odzimierz Ruka;
展开▼
作者单位

Department of Soft Tissue/Bone Sarcoma and Melanoma M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology Roentgena 5 02-781 Warsaw Poland;

Department of Soft Tissue/Bone Sarcoma and Melanoma M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology Roentgena 5 02-781 Warsaw Poland;

Center for Human Genetics University of Leuven Leuven 3000 Belgium;

Department of Radiology M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology 02-781 Warsaw Poland;

Department of Pathology M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology 02-781 Warsaw Poland;

Department of Biology and Genetics Medical University of Gdansk Gdansk Poland;

Department of Molecular Biology M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology 02-781 Warsaw Poland;

Department of Biology and Genetics Medical University of Gdansk Gdansk Poland;

Department of Molecular Biology M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology 02-781 Warsaw Poland;

Regional Oncological Center Gdansk Poland;

Department of General Surgery Jagiellonian University Cracow Poland;

Department of Soft Tissue/Bone Sarcoma and Melanoma M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology Roentgena 5 02-781 Warsaw Poland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Gastrointestinal stromal tumor; Imatinib; Prognosis; Predictive factors;

机译：胃肠道间质瘤;伊马替尼;预后;预测因素;

相似文献

外文文献
中文文献
专利

1. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. [J] . Rutkowski P, Nowecki Z, Nyckowski P, Journal of Surgical Oncology . 2006 ,第4期

机译：甲磺酸伊马替尼治疗期间最初无法手术和/或转移性胃肠道间质瘤（GIST）患者的手术治疗。
2. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with imatinib [J] . Mv Chandu de Silva, Robin Reid Pathology oncology research: POR . 2003 ,第1期

机译：胃肠道间质瘤（GIST）：C-kit突变，CD117表达，伊马替尼的鉴别诊断和靶向癌症治疗
3. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study [J] . Piotr Rutkowski, El?bieta Bylina, Anna Klimczak, BMC Cancer . 2012 ,第1期

机译：伊马替尼治疗失败后晚期胃肠道间质瘤（GIST）中舒尼替尼治疗的结果和预测因素-一项机构研究
4. International classifications of gastrointestinal stromal tumor: a clue for adjuvant imatinib treatment [C] . Tzen Chin-Yuan International Gastric Cancer Congress . 2011

机译：胃肠道间质瘤的国际分类：佐剂伊马替尼治疗的线索
5. Molecular mechanisms of response in gastrointestinal stromal tumors treated with imatinib mesylate [D] . McAuliffe, John Christopher 2007

机译：甲磺酸伊马替尼治疗胃肠道间质瘤的分子机制
6. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study [O] . Piotr Rutkowski, Elżbieta Bylina, Anna Klimczak, 2012

机译：伊马替尼治疗失败后晚期胃肠道间质瘤（GIST）中舒尼替尼治疗的结果和预测因素-一项机构研究
7. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study [O] . Piotr Rutkowski, Elżbieta Bylina, Anna Klimczak, 2012

机译：伊马替尼治疗失败后晚期胃肠道间质瘤（GIST）中舒尼替尼治疗的结果和预测因素-一项机构研究
8. Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy: Part 2, Imatinib for Gastrointestinal Stromal Tumors (GIST) [R] . Abernethy, A. P., McCrory, D. C. 2005

机译：关于口服癌疗法对医疗保险受益人与目前报道疗法的相对疗效的报告：第2部分，伊马替尼治疗胃肠道间质瘤（GIsT）

Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs)

摘要

著录项

相似文献

相关主题

期刊订阅